The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...
VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...
Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC development platform, which is designed to mask the cytotoxic payload carried by the ...
A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...
Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new ...
Autolus' CAR-T cell therapy for a rare and aggressive form of acute lymphoblastic leukaemia (ALL), Aucatzyl, has been recommended for conditional approval in the EU. The EMA's human medicines ...
As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive ...
The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...
An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...
In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...
Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...
Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results